Subcutaneous adipocytes from obese hyperinsulinemic women with polycystic ovary syndrome exhibit normal insulin sensitivity but reduced maximal insulin responsiveness

Erika Lystedt*, Hanna Westergren*, Jan Brynhildsen, Lotta Lindh-Åstrand, Johanna Gustavsson, Fredrik H Nyström, Mats Hammar and Peter Strålfors

Department of Cell Biology and Diabetes Research Centre, *Department of Molecular and Clinical Medicine and †Department of Medicine and Care, University of Linköping, SE58185 Linköping, Sweden

(Correspondence should be addressed to P Strålfors; Email: peter.stralfors@ibk.liu.se)

*E Lystedt and H Westergren contributed equally to this work

Abstract

Background: Polycystic ovary syndrome (PCOS) has a very high prevalence in women and is often associated with insulin resistance and aspects of the so-called metabolic syndrome.

Methods: Ten women diagnosed with PCOS were consecutively included (aged 21–39 years, average 30.2±1.9 years; body mass index 28.4–42.5 kg/m², average 37.5±1.7 kg/m² (mean±S.E.)). Adipocytes were isolated from the subcutaneous fat and, after overnight incubation to recover from insulin resistance due to the surgical cell isolation procedures, they were analyzed for insulin sensitivity.

Results: The patients with PCOS exhibited marked clinical hyperinsulinemia with 3.6-fold higher blood levels of C-peptide than a healthy lean control group (1.7±0.2 and 0.5±0.02 nmol/l respectively, P<0.0001). The patients with PCOS also exhibited 2.4-fold higher concentrations of serum triacylglycerol (2.1±0.3 and 0.9±0.06 mmol/l respectively, P<0.0001), but only slightly elevated blood pressure (118±12/76±6 and 113±7/72±6 mmHg respectively, P=0.055/0.046). However, insulin sensitivity for stimulation of glucose transport in the isolated adipocytes was indistinguishable from a non-PCOS, non-diabetic control group, while the maximal insulin effect on glucose uptake was significantly lower (2.2±0.2- and 3.8±0.8-fold respectively, P=0.02).

Conclusions: Subcutaneous adipocytes from patients with PCOS do not display reduced insulin sensitivity. The findings show that the insulin resistance of PCOS is qualitatively different from that of type 2 diabetes.
the level of insulin activation of protein kinase B (17). Incubation of the adipocytes overnight reverses this surgery/trauma-induced insulin resistance and allowed us to examine insulin resistance in type 2 diabetes without the interference from the surgery. Examination of adipocytes from patients with type 2 diabetes after overnight incubation thus reveals an insulin resistance to stimulation of glucose transport that is manifest at the level of insulin receptor phosphorylation/activation of the insulin receptor substrate 1 (17). Here, we have used this novel approach to examine insulin sensitivity for glucose uptake in adipocytes from obese patients diagnosed with PCOS, without interference from the surgical/trauma-induced insulin resistance. We report that whereas obese patients with PCOS exhibited strongly elevated levels of circulating C-peptide and fasting serum concentrations of triacylglycerol, their adipocytes exhibited normal insulin sensitivity but reduced maximal responsiveness to insulin.

**Materials and methods**

**Subjects**

Patients attending the department of obstetrics and gynecology at the University Hospital of Linköping for menstrual irregularities and/or hirsutism were consecutively recruited to the study if they displayed a testosterone/sex hormone binding globulin (SHBG) ratio of > 0.05 and had at least 36 days of menstrual interval over the last three cycles. In nine of the ten patients ultrasonographic examination of the ovaries was performed and revealed typical signs of polycystic ovaries. Ten women were included (aged 21–39 years, average 37.5 kg/m²). The patients were invited by mail to participate in this population study and participation rate was 67%. All these subjects underwent drawing of blood samples and recording of anthropometric parameters in the fasting state at 08.00 h. The detailed description of this population has been published (18).

**Isolation and incubation of adipocytes**

Adipocytes were isolated by collagenase (type 1, Worthington, Lakewood, NJ, USA) digestion as described (19). At a final concentration of 100 μl packed cell volume per ml, cells were incubated in Krebs-Ringer solution (60 mmol/l NaCl, 2.3 mmol/l KCl, 1.2 mmol/l CaCl₂, 0.6 mmol/l MgSO₄, 0.6 mmol/l KH₂PO₄) and DMEM cell medium at half concentration, containing 20 mmol/l Hepes, pH 7.40, 7% (w/v) fatty acid-free bovine serum albumin, 100 mmol/l phenylisopropyladenosine, 0.5 U/ml adenosine deaminase, 2 mmol/l glucose, 50 U/ml penicillin and 50 μg/ml streptomycin at 37°C for 20–24 h on a shaking water-bath (17). Before analysis, cells were washed and transferred to Krebs-Ringer solution. Insulin was from Sigma-Aldrich (St Louis, MO, USA).

**Determination of glucose transport**

Glucose transport was determined as uptake of 2-deoxy-D-[1-3H]glucose (17) after transfer of cells to medium without glucose. 2-Deoxy-D-[1-3H]glucose (Amersham Biotech, Uppsala, Sweden) was added to a final concentration of 50 μmol/l (10 μCi/ml) and the cells were incubated for 30 min. It was verified that uptake was linear for at least 30 min.

**Statistics**

Dose–response curves were compared using the F test with the sigmoidal curve-fitting algorithm in GraphPad Prism 4 (GraphPad Software, Inc., San Diego, CA, USA). The difference between groups was analyzed by Student’s t-test. The null hypothesis was rejected if P < 0.05.

**Results**

Characteristics of the patients with PCOS are shown in Tables 1 and 2. As a comparison, we have included data from a non-PCOS control group that was matched for age and gender. The PCOS patients were obese as judged by BMI (37.5±1.7 kg/m²; mean±s.e.m.). The fasting blood glucose was normal, but the patients with PCOS displayed considerably increased levels of fasting C-peptide (3.6-fold higher concentration compared with the non-PCOS controls) (Table 1). The fasting levels of triacylglycerol were also considerably increased in the patients (2.4-fold higher...
concentration). However, only 20% of the patients with PCOS responded to the oral glucose tolerance test with glucose levels above the diagnostic level for impaired glucose tolerance and all responded with glucose levels below the diagnostic level for diabetes (not shown and Table 1). The metabolic differences between controls and patients could be caused by obesity or factors more specifically related to the polycystic ovary syndrome. We therefore next isolated fat cells from patients with PCOS and from a group of patients with type 2 diabetes matched for BMI as well as from a non-diabetic, non-obese control group.

Adipocytes were isolated from the abdominal subcutaneous adipose tissue of the patients with PCOS and the rates of glucose transport in response to varying concentrations of insulin were examined. Insulin enhanced glucose transport by the adipocytes with half-maximal effect (EC$_{50}$) at 0.03 nmol/l insulin (Fig. 1). The EC$_{50}$ and the entire dose–response curve were similar to those obtained from a group of non-diabetic women without PCOS (EC$_{50}$ = 0.03, BMI = 23.4 ± 1.5 kg/m$^2$) (17) and therefore were also markedly more sensitive to insulin stimulation than cells from a group of type 2 diabetic women (EC$_{50}$ = 0.15) with an average BMI of 38.4 ± 4.0 kg/m$^2$ (17) (Fig. 1). This demonstrates that

Table 1 Clinical characteristics of the study (PCOS) and control groups.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PCOS (n = 10)</th>
<th>Controls (n = 46)</th>
<th>P value (Student’s t-test)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Average±S.E.</td>
<td>Range</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>30.2 ± 23–39</td>
<td>30.1 ± 0.97</td>
<td>0.97</td>
</tr>
<tr>
<td>BMI (kg/m$^2$)</td>
<td>37.5 ± 28.4–42.2</td>
<td>23.2 ± 0.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Blood pressure (mmHg)</td>
<td>118±12/76±6</td>
<td>113±772±6</td>
<td>0.055/0.046</td>
</tr>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td>5.0 ± 3.9–7.4</td>
<td>4.7 ± 0.1</td>
<td>0.11</td>
</tr>
<tr>
<td>C-peptide (mmol/l)</td>
<td>1.7 ± 0.88–2.87</td>
<td>0.5 ± 0.02</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Triacylglycerol (mmol/l)</td>
<td>2.1 ± 1.2–4.6</td>
<td>0.9 ± 0.6</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>5.4 ± 4.2–7.1</td>
<td>4.5 ± 0.1</td>
<td>0.0018</td>
</tr>
<tr>
<td>LDL-cholesterol</td>
<td>3.2 ± 2.4–4.7</td>
<td>2.8 ± 0.1</td>
<td>0.088</td>
</tr>
<tr>
<td>HDL-cholesterol</td>
<td>1.2 ± 0.9–1.5</td>
<td>1.3 ± 0.05</td>
<td>0.30</td>
</tr>
</tbody>
</table>

LDL, low density lipoprotein; HDL, high density lipoprotein.

Table 2 Serum concentrations in the PCOS study group (n = 10) and normal reference values.

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Concentration</th>
<th>Normal reference concentration range</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Average±S.E.</td>
<td>Range</td>
</tr>
<tr>
<td>Insulin (pmol/l)</td>
<td>216±59</td>
<td>76–696</td>
</tr>
<tr>
<td>Glucose 2 h after glucose load (mmol/l)</td>
<td>6.8 ± 2.5–10.7</td>
<td>&lt;7.9</td>
</tr>
<tr>
<td>Estradiol (pmol/l)</td>
<td>161±28</td>
<td>75–360</td>
</tr>
<tr>
<td>Progesterone (nmol/l)</td>
<td>1.4±0.1</td>
<td>&lt;1–13</td>
</tr>
<tr>
<td>LH (U/l)</td>
<td>8.0±1.0</td>
<td>2.0–12</td>
</tr>
<tr>
<td>FSH (U/l)</td>
<td>5.2±0.4</td>
<td>2.6–6.5</td>
</tr>
<tr>
<td>Testosterone (nmol/l)</td>
<td>2.2±0.1</td>
<td>1.6–2.8</td>
</tr>
<tr>
<td>SHBG (nmol/l)</td>
<td>20.3±2.5</td>
<td>9.7–37</td>
</tr>
<tr>
<td>Testosterone/SHBG ratio</td>
<td>0.14±0.02</td>
<td>0.08–0.29</td>
</tr>
</tbody>
</table>

For simplicity, reference ranges for estradiol, progesterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are given as follicular phase values as none of the patients had signs of ovulation according to menstrual history. Oral glucose tolerance was tested after an over-night fast and measurement of fasting glucose, ingestion of 75 g glucose and re-analysis of capillary blood glucose after 2h.

SHBG, sex hormone binding globulin.

Figure 1 Dose–response curves for stimulation of glucose transport by insulin. Adipocytes from patients with PCOS were incubated with insulin at the indicated concentrations for 10 min. Glucose transport was determined as uptake of 2-deoxy-D-[1-3H]glucose by the cells (solid circles, continuous line, mean±S.E., n = 10). Also plotted are the dose–response curve for a normal control group of women (open circles, dashed line, mean±S.E., n = 8) and for a group of type 2 diabetic women (triangles, dashed line, mean±S.E., n = 5) values taken from (17). The dose–response curve for the PCOS patients was significantly different from that of the type 2 diabetic women, P < 0.05, but not from the normal control group.
subcutaneous adipocytes in this obese group of patients with PCOS had normal insulin sensitivity for stimulation of glucose uptake. The basal and maximal insulin-stimulated glucose uptake varied widely between individuals, ranging from 18 to 98 nmol/min/l of cells (110 ± 15, n = 10) and from 44 to 173 nmol/min/l of cells (140 ± 33, n = 10) respectively, and were not significantly different from those of non-diabetic women without PCOS (17). The maximal insulin effect was, however, lower (P = 0.02) in adipocytes from the group of patients with PCOS (2.2 ± 0.2-fold stimulation, n = 10) compared with non-diabetic women without PCOS (3.8 ± 0.8-fold stimulation, n = 8) (17).

Discussion

The patients in our study were markedly obese compared with a non-PCOS control population. They also exhibited a marked hyperinsulinemia with, on average, 3.6-fold higher levels of fasting C-peptide than lean controls. Since fasting blood glucose concentrations were similar in the patients and in the control group this degree of C-peptide elevation is a clear indicator of resistance to the metabolic effects of insulin in combination with sufficient function of the pancreatic beta-cells. Such high production of insulin could have clinical implications for patients with PCOS since insulin has been shown to lower the levels of SHBG (20). Low levels of SHBG serve to increase the concentration of free testosterone resulting in hirsutism and acne. Despite clear signs of a reduction of the sensitivity to insulin in vivo we could not detect any differences in the insulin sensitivity to glucose uptake in adipocytes isolated from the patients with PCOS. We have previously reported that when fat cells are studied immediately after surgery, the insulin resistance following the surgical procedure and isolation of the cells masks differences in signaling that can be observed only when the adipocytes are allowed to recover by incubation overnight (17). Using this approach to examine the fat cells, we found no difference in the sensitivity to insulin in subcutaneous adipocytes from patients with PCOS as compared with non-PCOS women. The maximal insulin responsiveness was, however, reduced in the patients with PCOS compared with the control group. This is in contrast to findings in patients with type 2 diabetes whose adipocytes exhibit reduced insulin sensitivity, but normal insulin responsiveness (17). It is, of course, a distinct possibility that the visceral, but not subcutaneous, adipose tissue is insulin resistant in PCOS, in contrast to the situation in type 2 diabetes (17).

Ciaraldi et al. have studied the effects of insulin on insulin-induced glucose uptake in adipocytes from PCOS patients directly after cell isolation and found this to be clearly perturbed (14). Taken together, the results of our study and that by Ciaraldi et al. indicate a reversible insulin resistance in adipocytes from patients with PCOS, similar to the situation in cells directly after the surgical cell isolation procedure (17). This reversibility points to humoral rather than structural factors underlying the insulin resistance of the fat cells in PCOS, and is different from what we have previously shown to be the case in adipocytes from patients with overt type 2 diabetes, which is not reversible (17). It is possible that the rapidly reversible insulin resistance of isolated adipocytes is specific for patients with PCOS. It might, however, also represent a pre-diabetic state. The fact that the patients with PCOS did not exhibit lowered levels of circulating HDL (Table 1) is compatible with this. It should be noted, however, that the average BMI of these patients with PCOS was the same as in a group of women with type 2 diabetes, whose adipocytes were markedly insulin resistant in the same assay as used herein (17). In this context it is interesting that the indices commonly utilized to determine insulin resistance in diabetes, the quantitative insulin sensitivity check index (QUICKI) and the homeostasis model of assessment (HOMA), do not correlate with the euglycemic clamp determination of insulin sensitivity in women with PCOS in contrast to diabetes (21).

In conclusion, a group of very obese women with PCOS had a marked hyperinsulinemia as evidenced by high levels of circulating C-peptide, while their abdominal subcutaneous adipocytes displayed normal sensitivity for insulin stimulation of glucose transport, but reduced maximal responsiveness.

Acknowledgements

We thank Preben Kjolhede and Gheorghe Andreescu for supplying adipose tissue. This work was financially supported by research grants from Östergötland County Council, Linköping University Hospital Research Funds, the Swedish Diabetes Association, and the Swedish Research Council.

References

3 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocrine Reviews 1997 18 774–800.
5 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 2004 81 19–25.

www.eje-online.org


Received 11 May 2005
Accepted 1 September 2005